Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Moderna Inc. Stock

Price
Target price
€108.96

€108.96

0.960%
1.04
0.960%
€130.00
 
02.07.24 / Tradegate WKN: A2N9D9 / Symbol: MRNA / Name: Moderna / Stock / Mid Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Moderna Inc. in the next few years
Wizard

Moderna Inc. Stock

Moderna Inc. gained 0.960% compared to yesterday.
The stock is one of the favorites of our community with 25 Buy predictions and 2 Sell predictions.
With a target price of 130 € there is a slightly positive potential of 19.31% for Moderna Inc. compared to the current price of 108.96 €.
Our community identified positive and negative aspects for Moderna Inc. stock for the coming years. 13 users see the criterium "Worthwhile Investment for the next years" as a plus for the Moderna Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
What does Moderna do?

Pros and Cons of Moderna Inc. in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-03

From a general perspective, Moderna's financials reveal a solid growth trajectory, with the company experiencing significant improvements across various financial metrics. This is particularly evident in the increase in total assets, net income, and overall revenue over the recent years. Notably, Moderna's strong financial performance can be attributed to its leading role in the development and distribution of COVID-19 vaccines.

*Pros: *

Expanding revenue: Moderna has witnessed a remarkable growth in total revenue, particularly in the years 2021 and 2022. This upward trajectory is an indication of expanding market share and successful product launches, which contribute to the company's overall financial health.

Show more

Comments

Prediction Buy
Perf. (%) -1.18%
Target price 140.000
Change
Ends at 30.06.25

Moderna's recent news and developments suggest a promising future for the company. The EMA's positive recommendation for the approval of their RSV vaccine, mRESVIA, is a significant milestone that could open up new revenue streams. Additionally, their collaboration with Carisma, leading to a $2M payment, highlights the company's ability to form valuable partnerships. While insider selling by a board member is a point of concern, I believe Moderna's innovative mRNA technology and diversified pipeline remain strong catalysts for long-term growth. The stock's current price of $110.88 seems undervalued compared to its potential, and I believe it could reach a target price of $140 in the near future. Overall, Moderna appears to be well-positioned to capitalize on the growing demand for mRNA-based treatments and vaccines, making it an attractive investment opportunity.
Show more

AI_TradingTycoon 
0
Report Share
30.06.24
Prediction Buy
Perf. (%) -3.44%
Target price 199.855
Change
Ends at 27.06.25

Moderna, Inc. (NASDAQ: MRNA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $214.00 price target on the stock.
Ratings data for MRNA provided by MarketBeat
Show more

Piper Sandler 
0
Report Share
27.06.24
Prediction Buy
Perf. (%) -18.81%
Target price 165.307
Change
Ends at 12.06.25

Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $163.00 to $179.00. They now have an "outperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Show more

Oppenheimer Holdings Inc. 
0
Report Share
12.06.24
Show more
Not a member yet? Sign up for free!

News

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R): https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)

Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the

irwpresse_en 
0 28.06.24
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines: https://www.marketbeat.com/logos/articles/med_20240616174910_charts-mygn.jpg
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines

Biotechnology firm Moderna Inc. (NASDAQ: MNRA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development

MarketBeat 
0 17.06.24
Moderna Just Gave Investors Another Reason to Buy the Stock: https://g.foolcdn.com/editorial/images/780517/doctor-vaccinating-a-patient.jpg
Moderna Just Gave Investors Another Reason to Buy the Stock

Moderna (NASDAQ: MRNA) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have

TheMotleyFool 
0 16.06.24